312 related articles for article (PubMed ID: 21784113)
1. Covalently stabilized trimethyl chitosan-hyaluronic acid nanoparticles for nasal and intradermal vaccination.
Verheul RJ; Slütter B; Bal SM; Bouwstra JA; Jiskoot W; Hennink WE
J Control Release; 2011 Nov; 156(1):46-52. PubMed ID: 21784113
[TBL] [Abstract][Full Text] [Related]
2. Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen.
Slütter B; Bal S; Keijzer C; Mallants R; Hagenaars N; Que I; Kaijzel E; van Eden W; Augustijns P; Löwik C; Bouwstra J; Broere F; Jiskoot W
Vaccine; 2010 Aug; 28(38):6282-91. PubMed ID: 20638455
[TBL] [Abstract][Full Text] [Related]
3. Efficient induction of immune responses through intradermal vaccination with N-trimethyl chitosan containing antigen formulations.
Bal SM; Slütter B; van Riet E; Kruithof AC; Ding Z; Kersten GF; Jiskoot W; Bouwstra JA
J Control Release; 2010 Mar; 142(3):374-83. PubMed ID: 19932723
[TBL] [Abstract][Full Text] [Related]
4. Antigen-adjuvant nanoconjugates for nasal vaccination: an improvement over the use of nanoparticles?
Slütter B; Bal SM; Que I; Kaijzel E; Löwik C; Bouwstra J; Jiskoot W
Mol Pharm; 2010 Dec; 7(6):2207-15. PubMed ID: 21043518
[TBL] [Abstract][Full Text] [Related]
5. Adjuvanted, antigen loaded N-trimethyl chitosan nanoparticles for nasal and intradermal vaccination: adjuvant- and site-dependent immunogenicity in mice.
Bal SM; Slütter B; Verheul R; Bouwstra JA; Jiskoot W
Eur J Pharm Sci; 2012 Mar; 45(4):475-81. PubMed ID: 22009113
[TBL] [Abstract][Full Text] [Related]
6. Mechanistic study of the adjuvant effect of biodegradable nanoparticles in mucosal vaccination.
Slütter B; Plapied L; Fievez V; Sande MA; des Rieux A; Schneider YJ; Van Riet E; Jiskoot W; Préat V
J Control Release; 2009 Sep; 138(2):113-21. PubMed ID: 19445980
[TBL] [Abstract][Full Text] [Related]
7. N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model.
Amidi M; Romeijn SG; Verhoef JC; Junginger HE; Bungener L; Huckriede A; Crommelin DJ; Jiskoot W
Vaccine; 2007 Jan; 25(1):144-53. PubMed ID: 16973248
[TBL] [Abstract][Full Text] [Related]
8. Conjugation of ovalbumin to trimethyl chitosan improves immunogenicity of the antigen.
Slütter B; Soema PC; Ding Z; Verheul R; Hennink W; Jiskoot W
J Control Release; 2010 Apr; 143(2):207-14. PubMed ID: 20074597
[TBL] [Abstract][Full Text] [Related]
9. Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery.
Sayin B; Somavarapu S; Li XW; Thanou M; Sesardic D; Alpar HO; Senel S
Int J Pharm; 2008 Nov; 363(1-2):139-48. PubMed ID: 18662762
[TBL] [Abstract][Full Text] [Related]
10. Dual role of CpG as immune modulator and physical crosslinker in ovalbumin loaded N-trimethyl chitosan (TMC) nanoparticles for nasal vaccination.
Slütter B; Jiskoot W
J Control Release; 2010 Nov; 148(1):117-121. PubMed ID: 20600405
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis B surface antigen nanoparticles coated with chitosan and trimethyl chitosan: Impact of formulation on physicochemical and immunological characteristics.
Tafaghodi M; Saluja V; Kersten GF; Kraan H; Slütter B; Amorij JP; Jiskoot W
Vaccine; 2012 Aug; 30(36):5341-8. PubMed ID: 22749834
[TBL] [Abstract][Full Text] [Related]
12. Chitosan and trimethyl chitosan chloride (TMC) as adjuvants for inducing immune responses to ovalbumin in mice following nasal administration.
Boonyo W; Junginger HE; Waranuch N; Polnok A; Pitaksuteepong T
J Control Release; 2007 Aug; 121(3):168-75. PubMed ID: 17644205
[TBL] [Abstract][Full Text] [Related]
13. Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems.
Mohanan D; Slütter B; Henriksen-Lacey M; Jiskoot W; Bouwstra JA; Perrie Y; Kündig TM; Gander B; Johansen P
J Control Release; 2010 Nov; 147(3):342-9. PubMed ID: 20727926
[TBL] [Abstract][Full Text] [Related]
14. Tailorable thiolated trimethyl chitosans for covalently stabilized nanoparticles.
Verheul RJ; van der Wal S; Hennink WE
Biomacromolecules; 2010 Aug; 11(8):1965-71. PubMed ID: 20578733
[TBL] [Abstract][Full Text] [Related]
15. Small is beautiful: N-trimethyl chitosan-ovalbumin conjugates for microneedle-based transcutaneous immunisation.
Bal SM; Slütter B; Jiskoot W; Bouwstra JA
Vaccine; 2011 May; 29(23):4025-32. PubMed ID: 21443959
[TBL] [Abstract][Full Text] [Related]
16. Preparation and characterization of protein-loaded N-trimethyl chitosan nanoparticles as nasal delivery system.
Amidi M; Romeijn SG; Borchard G; Junginger HE; Hennink WE; Jiskoot W
J Control Release; 2006 Mar; 111(1-2):107-16. PubMed ID: 16380189
[TBL] [Abstract][Full Text] [Related]
17. TMC-MCC (N-trimethyl chitosan-mono-N-carboxymethyl chitosan) nanocomplexes for mucosal delivery of vaccines.
Sayin B; Somavarapu S; Li XW; Sesardic D; Senel S; Alpar OH
Eur J Pharm Sci; 2009 Nov; 38(4):362-9. PubMed ID: 19733658
[TBL] [Abstract][Full Text] [Related]
18. Development and characterization of chitosan coated poly-(ɛ-caprolactone) nanoparticulate system for effective immunization against influenza.
Gupta NK; Tomar P; Sharma V; Dixit VK
Vaccine; 2011 Nov; 29(48):9026-37. PubMed ID: 21939718
[TBL] [Abstract][Full Text] [Related]
19. Relationship between structure and adjuvanticity of N,N,N-trimethyl chitosan (TMC) structural variants in a nasal influenza vaccine.
Hagenaars N; Verheul RJ; Mooren I; de Jong PH; Mastrobattista E; Glansbeek HL; Heldens JG; van den Bosch H; Hennink WE; Jiskoot W
J Control Release; 2009 Dec; 140(2):126-33. PubMed ID: 19712713
[TBL] [Abstract][Full Text] [Related]
20. Antigen-conjugated N-trimethylaminoethylmethacrylate chitosan nanoparticles induce strong immune responses after nasal administration.
Liu Q; Zheng X; Zhang C; Shao X; Zhang X; Zhang Q; Jiang X
Pharm Res; 2015 Jan; 32(1):22-36. PubMed ID: 24970313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
